Clinuvel's company releases, including archives.
Form 603: Notice of Initial Substantial Holder
Request for Trading Halt
Investors' Blog Posts
In 2010, Clinuvel announced that it would commence a clinical trial of a new drug for vitiligo. In late 2012 the first treatment results...Read More
Clinuvel Non-Executive Director Brenda Shanahan has been honoured at The Australian Financial Review and Westpac Group Woman of Influence...Read More
Since we publicly announced our vitiligo program in 2010, the entire Clinuvel team has aimed to gain a better understand this disease, its...Read More